Compare AVXL & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | BRBI |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.9M | 394.5M |
| IPO Year | 2013 | N/A |
| Metric | AVXL | BRBI |
|---|---|---|
| Price | $4.19 | $14.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 826.5K | 3.2K |
| Earning Date | 02-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.01% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.24 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $12.54 |
| 52 Week High | $13.99 | $67.01 |
| Indicator | AVXL | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 46.08 |
| Support Level | $3.60 | $13.82 |
| Resistance Level | $5.27 | $14.34 |
| Average True Range (ATR) | 0.27 | 0.23 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 11.20 | 20.29 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.